Clinical Trials

136 enrolled

Triple Negative Breast Neoplasms

NCT03961698 2023-08-14

MARIO-3

91 enrolled

BreastGenitourinary

Breast Neoplasms, Carcinoma, Renal Cell, Triple Negative Breast Neoplasms

NCT05957939 2023-07-24

Targeting Metastatic Breast Cancers by Alkaline Glucosodiene Molecules Via a Metabolic Pathway Phase I Clinical Trial

2 enrolled

Triple Negative Breast Neoplasms

NCT05928780 2023-07-03

An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC in First-line Treatment (FUTURE-Trop2)

125 enrolled

Triple Negative Breast Neoplasms

NCT03920488 2023-06-28

PERSONA

264 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05910710 2023-06-20

Impact of Immuno-Oncologic Agent on Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

50 enrolled

Triple Negative Breast Neoplasms

NCT03567720 2023-06-01

Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC

65 enrolled

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT05302778 2023-05-25

HERMIONE-10

200 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05872412 2023-05-25

Effect of Platinum-based Versus Non-platinum-based Neoadjuvant Chemotherapy in Triple-negative Breast Cancer

82 enrolled

Triple Negative Breast Neoplasms

NCT05763992 2023-05-18

BREAKFAST-2

145 enrolled

Pathologic Complete Response, Breast Neoplasms, Fasting, Triple Negative Breast Neoplasms

NCT05831553 2023-05-06

TIP

100 enrolled

Triple Negative Breast Neoplasms

NCT05556200 2023-04-12

A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs

58 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05746728 2023-04-06

Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer

45 enrolled

Triple Negative Breast Neoplasms

NCT05769491 2023-03-15

Looking At Triple Negative Breast Cancer Patient Experience Patterns in Medical Trials

500 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04365790 2023-03-08

Investigation of Gene Mutations in Patients With Triple-negative and Patients With HER2+ Breast Cancer Adenocarcinoma

500 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03475953 2023-03-03

REGOMUNE

BreastEndocrineGastrointestinalGenitourinaryHead & NeckNETOther solid neoplasmSarcomaThoracic

747 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Turcot syndrome, Tertiary Lymphoid Structures, Mesothelioma, Malignant, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Thyroid Neoplasms, Triple Negative Breast Neoplasms

NCT05670925 2023-02-28

A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC.

46 enrolled

Triple Negative Breast Neoplasms

NCT05453825 2023-01-31

A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors

BreastGastrointestinalGynecologic

180 enrolled

Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT05692661 2023-01-20

A Dose Escalation Study of Proton and Carbon Ion Irradiation for HER2 Positive and Triple Negative Breast Cancer

24 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04248998 2023-01-18

BREAKFAST

30 enrolled

Phase EARLY_PHASE1 Unknown

Triple Negative Breast Neoplasms

NCT05680662 2023-01-11

The Study of Quadruple Therapy Quercetin, Zinc, Metformin, and EGCG as Adjuvant Therapy for Early, Metastatic Breast Cancer and Triple-negative Breast Cancer, a Novel Mechanism

200 enrolled

Triple Negative Breast Neoplasms

NCT05390476 2022-11-04

Tucidinostat and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label, Randomized Controlled, Phase II Clinical Trial

126 enrolled

Triple Negative Breast Neoplasms

NCT03907800 2022-10-27

NeoPATH

100 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05546255 2022-09-19

Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer

40 enrolled

Triple Negative Breast Neoplasms

NCT03720431 2022-08-17

TTAC-0001 and Pembrolizumab Phase Ib Combination Trial in Metastatic Triple-negative Breast Cancer

11 enrolled

Triple Negative Breast Neoplasms

NCT03805399 2022-08-10

FUTURE

140 enrolled

Triple Negative Breast Neoplasms

NCT05491694 2022-08-08

HIFU

20 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04297267 2022-07-22

nonpCR GP

100 enrolled

Triple Negative Breast Neoplasms

NCT05461690 2022-07-18

Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination Deficiency

50 enrolled

Triple Negative Breast Neoplasms

NCT04460456 2022-06-30

A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors

BreastGastrointestinalGynecologicHead & NeckThoracic

58 enrolled

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05438706 2022-06-30

A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer

70 enrolled

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT05303038 2022-06-09

Castle06(BC)

15 enrolled

Triple Negative Breast Neoplasms

NCT05402722 2022-06-02

Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer

30 enrolled

Triple Negative Breast Neoplasms

NCT02341911 2022-04-20

TNBC

150 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03251313 2022-04-20

PD-1(Programmed Death-1) Antibody +GP as First Line Treatment for Triple Negative Breast Cancer(TNBC) Patients

31 enrolled

Triple Negative Breast Neoplasms

NCT04192903 2022-04-20

Chidamide Combined With Cisplatin for Relapsed or Metastatic Triple-negative Breast Cancer

55 enrolled